Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to “Hold”

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other research firms also recently weighed in on KLRS. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday, May 13th. Citizens Jmp dropped their price target on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. TD Cowen assumed coverage on Kalaris Therapeutics in a research report on Monday, June 15th. They set a “buy” rating on the stock. Weiss Ratings cut Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Finally, Wedbush started coverage on Kalaris Therapeutics in a research note on Thursday, May 14th. They issued an “outperform” rating and a $17.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.75.

Kalaris Therapeutics Price Performance

Shares of NASDAQ:KLRS opened at $3.90 on Friday. The company’s fifty day moving average price is $4.13 and its 200 day moving average price is $5.58. Kalaris Therapeutics has a 12 month low of $3.03 and a 12 month high of $11.88. The firm has a market capitalization of $92.86 million, a P/E ratio of -1.93 and a beta of 0.22.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. On average, sell-side analysts anticipate that Kalaris Therapeutics will post -1.99 EPS for the current year.

Institutional Trading of Kalaris Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nano Cap New Millennium Growth Fund L P purchased a new position in Kalaris Therapeutics in the 4th quarter valued at $34,000. Sigma Planning Corp purchased a new stake in Kalaris Therapeutics in the 2nd quarter valued at approximately $41,000. Barclays PLC acquired a new position in Kalaris Therapeutics during the 4th quarter worth approximately $51,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $58,000. Finally, XTX Topco Ltd acquired a new stake in shares of Kalaris Therapeutics in the 2nd quarter valued at approximately $65,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.